The overexpression of PD-1 is associated with a favorable prognosis in autoimmune diseases as it contributes to the exhaustion of CD8+ T cells; however, PD-1 inhibitors may exacerbate the symptoms in individuals with MG (32). Here, PDCD1 is linked to myasthenia gravis.